# Thymol (from Thymus vulgaris and related species)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/thymol-from-thymus-vulgaris-and-related-species
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-02
**Evidence Score:** 1 / 10
**Category:** Compound
**Also Known As:** CAS 89-83-8, 5-methyl-2-(1-methylethyl)phenol, isopropyl cresol, thyme camphor, 2-isopropyl-5-methylphenol, Thymol (from Thymus vulgaris and related Lamiaceae species)

## Overview

Thymol is a phenolic monoterpene (C₁₀H₁₄O, MW 150.22 g/mol) that exerts [antimicrobial](/ingredients/condition/immune-support) activity primarily by disrupting phospholipid bilayers of bacterial cell membranes, causing ion leakage and cell death, while its [antioxidant](/ingredients/condition/antioxidant) action involves direct radical scavenging via its phenolic hydroxyl group. In meta-analyzed in vitro data, thymol inhibits a broad spectrum of bacteria at minimal inhibitory concentrations of 150–400 mg/L, reduces established Pseudomonas aeruginosa biofilms by up to 99.6% at 0.041% (v/v), and induces apoptosis in cancer cell lines at 50 μM via Bcl-2 downregulation and caspase-3/9 activation.

## Health Benefits

- **Broad-Spectrum [Antimicrobial](/ingredients/condition/immune-support) Activity**: Thymol disrupts bacterial and fungal cell membranes through intercalation into the phospholipid bilayer, with MICs of 150–400 mg/L for most clinically relevant Gram-positive and Gram-negative bacteria; it demonstrates particular potency against biofilm-forming pathogens such as P. aeruginosa, achieving 98.4–99.6% biofilm reduction at 0.041% (v/v).
- **Antioxidant Protection**: The phenolic hydroxyl group of thymol donates hydrogen atoms to neutralize [reactive oxygen species](/ingredients/condition/antioxidant) (ROS), with in vitro studies consistently showing DPPH and ABTS radical scavenging activity comparable to synthetic antioxidants; this activity is potentiated in the presence of co-occurring carvacrol and other terpenoids in whole essential oil fractions.
- **Anti-Inflammatory Effects**: Thymol suppresses NF-κB pathway activation and reduces [pro-inflammatory cytokine](/ingredients/condition/inflammation) production (TNF-α, IL-6, IL-1β) in macrophage cell models; these effects are attributed to inhibition of cyclooxygenase enzymes and modulation of arachidonic acid [metabolism](/ingredients/condition/weight-management), though human clinical validation remains pending.
- **Apoptosis Induction in Cancer Cell Lines**: At 50 μM, thymol decreases anti-apoptotic Bcl-2 expression, increases pro-apoptotic Bax, and activates caspase-3 and caspase-9, leading to programmed cell death in multiple in vitro cancer models; dose-dependent DNA damage is observed at 20–100 μM, underscoring a dual cytotoxic mechanism that requires careful concentration management.
- **Gastrointestinal Health Support**: Thymol-containing preparations have demonstrated preclinical benefits for gut microbiota modulation and [intestinal barrier integrity](/ingredients/condition/gut-health), with encapsulated formulations achieving five-fold higher jejunal retention (333 ng/g vs. 69 ng/g) compared to free thymol in porcine oral bioavailability studies, suggesting targeted luminal activity. The compound's spasmolytic and carminative properties have been documented in traditional and pharmacognostic literature as mechanisms underlying GI symptom relief.
- **Antifungal Activity**: Thymol disrupts fungal membrane ergosterol organization and inhibits cell wall synthesis enzymes, demonstrating activity against Candida species and dermatophytes in vitro; it is included in several topical antifungal formulations exploiting this mechanism for superficial mycosis management.
- **Oral Health and Dental Applications**: Thymol is an active ingredient in commercial antiseptic mouthwashes and dental varnishes, reducing oral biofilm formation by inhibiting glucosyltransferase enzymes in Streptococcus mutans and disrupting periodontal pathogen membranes; this represents one of the most well-validated practical applications of thymol's antimicrobial properties.

## Mechanism of Action

Thymol's primary [antimicrobial](/ingredients/condition/immune-support) mechanism involves the incorporation of its lipophilic monoterpene structure into microbial phospholipid bilayers, increasing membrane fluidity and permeability, which causes dissipation of the proton motive force, leakage of intracellular ions (K⁺, ATP), and ultimately cell lysis; this membrane-disruptive action is concentration-dependent and operates at MICs of 150–400 mg/L for most bacteria. At the molecular level, thymol's phenolic hydroxyl group engages in hydrogen bonding with membrane phospholipid head groups while the isopropyl and methyl substituents penetrate the hydrophobic core, with Gram-negative bacteria showing slightly higher MICs (median ~400 mg/L) due to the additional outer membrane lipopolysaccharide barrier. In mammalian cells at higher concentrations (20–100 μM), thymol induces apoptosis through the intrinsic [mitochondrial](/ingredients/condition/energy) pathway: it downregulates the anti-apoptotic protein Bcl-2, upregulates pro-apoptotic Bax, triggers cytochrome c release, and sequentially activates caspase-9 and caspase-3, culminating in DNA fragmentation. As an [antioxidant](/ingredients/condition/antioxidant), thymol acts through direct hydrogen atom transfer (HAT) and single electron transfer (SET) mechanisms mediated by its phenolic –OH group, and may also upregulate endogenous antioxidant enzymes (superoxide dismutase, catalase) via Nrf2/ARE pathway modulation, though this latter pathway requires further in vivo confirmation.

## Clinical Summary

No human randomized controlled trials with defined sample sizes, primary endpoints, or effect size metrics for thymol as an isolated compound were identified in the searched literature, representing a significant gap between robust preclinical data and clinical validation. The compound's role in thyme-based herbal preparations (e.g., Bronchipret, a thyme-ivy syrup studied in respiratory tract infections) is supported by some clinical data, but these studies evaluate the whole extract rather than isolated thymol, making attribution to thymol specifically difficult. Preclinical evidence is internally consistent regarding [antimicrobial](/ingredients/condition/immune-support) MIC ranges, biofilm disruption percentages, and apoptosis induction concentrations, lending moderate confidence to mechanism of action claims. Confidence in therapeutic dosing recommendations for humans, drug interaction profiles, and long-term safety remains low, and regulatory bodies such as the European Medicines Agency classify thyme herb preparations under 'traditional use' designation rather than 'well-established use,' reflecting this evidence gap.

## Nutritional Profile

Thymol is a pure phenolic monoterpene compound (C₁₀H₁₄O, MW 150.22 g/mol) and does not function as a macronutrient, micronutrient, or caloric source in any meaningful dietary quantity. As a phytochemical, it is present in fresh thyme herb at concentrations of approximately 0.8–2.5 mg/g fresh weight within the essential oil fraction (which comprises roughly 0.5–2.5% of fresh herb weight), meaning typical culinary use delivers trace microgram-to-low milligram quantities of thymol. Its lipophilic character (log P ≈ 3.3) governs distribution behavior: absorption occurs readily across lipid membranes, distribution into fatty tissues is favored, and hepatic phase-II conjugation (glucuronidation, sulfation) governs elimination. Bioavailability is significantly impacted by formulation—encapsulated thymol achieves five-fold greater intestinal tissue retention versus free form in porcine models—and is expected to be enhanced when consumed with dietary fats due to enhanced micellar solubilization.

## Dosage & Preparation

- **Thyme Essential Oil (topical/aromatherapy)**: Typically diluted to 1–5% in carrier oil for topical [antimicrobial](/ingredients/condition/immune-support) or [anti-inflammatory](/ingredients/condition/inflammation) applications; thymol content of the oil ranges 30–46% in Thymus vulgaris, so a 2% dilution delivers approximately 0.6–0.9% thymol by weight.
- **Thyme Essential Oil (oral herbal preparations)**: Traditional and European Pharmacopoeia-aligned oral thyme preparations use dried herb equivalent to provide 1–2 g dried thyme per dose, 3× daily; no standardized thymol dose for oral use in isolated form is established in human guidelines.
- **Isolated Thymol (experimental/preclinical)**: In vitro and porcine studies use 150–400 mg/L for antimicrobial endpoints and 20–100 μM for cytotoxic assessments; no validated oral human dose exists.
- **Encapsulated Thymol (novel delivery)**: Sealed-heating microencapsulation achieves 5× higher jejunal retention versus free thymol in porcine models (333 ng/g vs. 69 ng/g), representing a promising controlled-release approach currently under preclinical development.
- **Mouthwash/Dental Formulations**: Thymol at 0.064% is an active ingredient in established antiseptic mouthwash formulations (e.g., Listerine original); this represents the most clinically validated concentration for oral antimicrobial use.
- **Hydrodistillation Extract**: Yields up to 49.0% thymol; supercritical CO₂ extraction at 40°C and 10.4–16.7 MPa yields 1.7–2.49× higher thymol content, preferred for pharmaceutical-grade standardization.
- **Timing Notes**: For GI-targeted effects, encapsulated forms are theoretically preferable to free thymol to survive gastric acid and maximize intestinal delivery; no human pharmacokinetic data confirm optimal administration timing.

## Safety & Drug Interactions

At concentrations used in food flavoring and established dental antiseptic formulations (≤0.064%), thymol is generally recognized as safe (GRAS) by the FDA; however, at higher experimental concentrations (20–100 μM in vitro), dose-dependent genotoxicity including DNA strand breaks and chromosomal damage has been documented, and the clinical relevance of this finding at achievable human tissue concentrations remains unresolved. Ingestion of undiluted thyme essential oil (containing 30–46% thymol) can cause gastrointestinal irritation, nausea, vomiting, and in large doses, systemic toxicity including respiratory depression; the oral LD₅₀ for thymol in rodents is approximately 980 mg/kg, placing it in a moderate acute toxicity category. No well-characterized drug interaction studies for isolated thymol in humans exist; theoretical interactions include potentiation of anticoagulant effects (given phenolic compounds' known platelet-aggregation modulation), and potential interference with CYP450 enzyme-metabolized drugs given thymol's hepatic [metabolism](/ingredients/condition/weight-management) via glucuronidation and sulfation pathways. Thymol-containing preparations should be used with caution during pregnancy and lactation due to the absence of safety data and the compound's emmenagogue reputation in traditional use; individuals with thyroid disorders should also exercise caution, as high-dose thyme preparations have been associated with [thyroid function](/ingredients/condition/hormonal) interference in isolated reports.

## Scientific Research

The evidence base for thymol consists predominantly of in vitro [antimicrobial](/ingredients/condition/immune-support) studies, computational pharmacology analyses, and limited animal (primarily porcine) pharmacokinetic investigations, with no rigorously designed randomized controlled trials in human populations identified in the current literature. A meta-analysis of MIC data across numerous bacterial strains established median inhibitory concentrations of 317 mg/L for Gram-positive organisms and 400 mg/L for Gram-negatives, though extreme variability (MIC range reported up to 183,505 mg/L) reflects substantial methodological heterogeneity across laboratories, culture conditions, and bacterial strains. Porcine oral pharmacokinetic studies have provided the most quantitative bioavailability data, demonstrating peak plasma concentrations (C_max) of 3.6–3.8 μg/mL for both free and sealed-heating encapsulated thymol, with encapsulation increasing jejunal tissue retention five-fold (333 ng/g vs. 69 ng/g); systemic organ accumulation remained low (37–58 ng/g), suggesting predominantly local GI action. Apoptosis and genotoxicity studies in cancer cell lines provide mechanistic insights at defined concentrations (50 μM and 20–100 μM respectively), but translation to human therapeutic dosing, safety margins, and clinical endpoints remains unestablished, placing overall evidence quality firmly in the preclinical category.

## Historical & Cultural Context

Thyme (Thymus vulgaris) has been used medicinally since antiquity, with records from ancient Egypt documenting its use as a preservative and embalming agent, and ancient Greek and Roman physicians including Dioscorides and Pliny the Elder prescribing thyme-based preparations for respiratory ailments, digestive complaints, and wound infection. In medieval European herbalism, thyme was a cornerstone of monastic pharmacopeias, used as an expectorant, antispasmodic, and [antimicrobial](/ingredients/condition/immune-support) remedy, with thymol isolation first achieved by the German pharmacist Caspar Neumann in 1719 and structural characterization completed in the 19th century. Traditional Ayurvedic medicine employs ajwain (Trachyspermum ammi), another high-thymol plant, extensively for digestive disorders, flatulence, and respiratory infections, with preparations including decoctions, powders, and steam inhalation. The identification of thymol as the principal active constituent of thyme oil by chemists in the 1800s catalyzed its commercial development as a synthetic antiseptic, leading to its incorporation into Listerine mouthwash (launched 1879) and serving as a precursor to the development of thymol iodide (aristol) as a surgical antiseptic in the late 19th century.

## Synergistic Combinations

Thymol and carvacrol, which frequently co-occur in thyme essential oils (carvacrol ranging 0.1–74.5% depending on chemotype), exhibit well-documented synergistic [antimicrobial](/ingredients/condition/immune-support) effects, with combined MICs significantly lower than either compound alone due to complementary membrane disruption mechanisms targeting different phospholipid binding sites; this synergy is particularly notable against antibiotic-resistant strains and biofilm-forming organisms. Thymol combined with conventional antibiotics such as tetracycline or ciprofloxacin has demonstrated synergistic or additive effects in vitro against Staphylococcus aureus and Escherichia coli, potentially by increasing membrane permeability and facilitating antibiotic entry into bacterial cells, though this combination requires clinical safety evaluation before therapeutic application. In [antioxidant](/ingredients/condition/antioxidant) contexts, thymol's efficacy is enhanced in the presence of other phenolic compounds such as rosmarinic acid and luteolin (co-occurring in Thymus vulgaris extracts), which together engage multiple complementary radical-scavenging pathways including HAT, SET, and Nrf2/ARE gene expression modulation.

## Frequently Asked Questions

### What is thymol and what plants contain it?

Thymol (C₁₀H₁₄O) is a phenolic monoterpene naturally occurring in the essential oils of thyme (Thymus vulgaris), ajwain (Trachyspermum ammi), and savory species (Satureja thymbra). In Thymus vulgaris, thymol typically comprises 30.88–46.02% of the total essential oil, making it the dominant bioactive constituent; ajwain oil contains approximately 17.41% thymol, and some Satureja species reach 33.8%. The compound is also produced synthetically for industrial and pharmaceutical applications.

### How does thymol kill bacteria?

Thymol kills bacteria primarily by inserting its lipophilic monoterpene structure into the bacterial phospholipid bilayer, increasing membrane permeability and causing leakage of vital intracellular contents including potassium ions and ATP. This disruption dissipates the proton motive force essential for bacterial energy production, ultimately leading to cell death. Minimal inhibitory concentrations (MICs) range from 150–400 mg/L for most clinically relevant bacteria, with Gram-negative organisms requiring slightly higher concentrations due to their protective outer membrane.

### Is thymol safe to consume or apply topically?

Thymol is recognized as GRAS (Generally Recognized as Safe) by the FDA at levels used in food flavoring, and at 0.064% it is an established active ingredient in antiseptic mouthwashes. However, undiluted thyme essential oil containing high levels of thymol should never be ingested, as it can cause gastrointestinal irritation, nausea, and systemic toxicity; the oral LD₅₀ in rodents is approximately 980 mg/kg. In vitro studies have observed dose-dependent DNA damage at 20–100 μM, though whether these concentrations are achievable in human tissues at normal supplemental doses is not yet established.

### What is the difference between thymol and carvacrol?

Thymol and carvacrol are structural isomers—both are phenolic monoterpenes with the molecular formula C₁₀H₁₄O—differing only in the position of the hydroxyl group on the aromatic ring: thymol has the –OH at the 2-position relative to the isopropyl group, while carvacrol has it at the 5-position. Both compounds disrupt microbial membranes via similar mechanisms and frequently co-occur in thyme and oregano essential oils, and they exhibit synergistic antimicrobial effects when combined. Carvacrol is the dominant phenol in oregano-type chemotypes, while thymol predominates in thyme-type chemotypes of Thymus vulgaris.

### Does thymol have proven anticancer effects in humans?

Thymol has demonstrated apoptosis-inducing effects in multiple cancer cell lines at 50 μM—decreasing Bcl-2, increasing Bax, and activating caspase-3 and caspase-9—but these are strictly in vitro findings with no corresponding human clinical trial data. Dose-dependent DNA damage is also observed at 20–100 μM in cell culture models, which is a mechanistically plausible but unvalidated anticancer pathway. No human randomized controlled trials evaluating thymol as an anticancer agent have been published, and the compound should not be considered a cancer treatment based on current evidence.

### What is the most effective concentration of thymol for killing bacteria and fungi?

Thymol demonstrates antimicrobial efficacy at minimum inhibitory concentrations (MICs) of 150–400 mg/L against most clinically relevant bacteria, with particularly strong activity against biofilm-forming pathogens like Pseudomonas aeruginosa at concentrations as low as 0.041% (v/v), achieving 98.4–99.6% biofilm reduction. The effective concentration varies depending on the target microorganism, bacterial susceptibility profile, and whether the pathogen is planktonic or biofilm-associated. For topical applications, lower concentrations (0.05–0.5%) are typically used, while oral formulations generally employ smaller doses due to thymol's potency and lipophilic nature.

### Are there specific populations who should avoid thymol supplements or products?

Individuals with thyroid disorders should exercise caution with thymol, as thymus-derived compounds may influence thyroid function; those with a history of allergic reactions to Thymus vulgaris or related aromatics should avoid it. Pregnant and nursing women should consult healthcare providers before using thymol supplements, as safety data in these populations is limited. People taking anticoagulants or platelet-inhibiting medications should be aware that thymol may have mild antiplatelet properties at high doses, potentially requiring dose adjustments or monitoring.

### How does thymol's mechanism of action compare to conventional antibiotics, and is microbial resistance a concern?

Thymol disrupts bacterial and fungal cell membranes through direct intercalation into the phospholipid bilayer, a different mechanism from most conventional antibiotics that target protein synthesis or cell wall synthesis, potentially making it effective against some antibiotic-resistant strains. Resistance development to thymol appears slower than to traditional antibiotics due to this broad membrane-disruption approach, though prolonged exposure at subinhibitory concentrations could theoretically select for tolerant populations. Limited clinical data currently exists on resistance emergence in long-term human use, distinguishing thymol from well-studied pharmaceuticals with established resistance profiles.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*